Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) (CLAVELA)
This study is ongoing, but not recruiting participants.
Sponsor:
Clavis Pharma
Information provided by (Responsible Party):
Clavis Pharma
ClinicalTrials.gov Identifier:
NCT01147939
First received: April 14, 2010
Last updated: January 31, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is ongoing, but not recruiting participants. |
|---|---|
| Estimated Study Completion Date: | June 2013 |
| Estimated Primary Completion Date: | June 2013 (Final data collection date for primary outcome measure) |